Clinical trial
Amifostine and Combination Chemotherapy in Treating Patients With Newly…
NCT00003268 · Sidney Kimmel Cancer Center at Thomas Jefferson University, Other · Completed
Key facts
| NCT number | NCT00003268 |
|---|---|
| Title | Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Official title | A Phase I Study of Cytosine Arabinoside, Idarubicin, and Amifostine as Induction Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Lead sponsor | Sidney Kimmel Cancer Center at Thomas Jefferson University, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Leukemia |
| Intervention type | Drug |
| Interventions | amifostine trihydrate, cytarabine, idarubicin |
| Start date | Jan 1, 1998 |
| Completion | Dec 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: